Yarrow Bioscience advances YB-101: FDA Fast Track, Phase 2a/2b trial started

VYNE Therapeutics Inc.

In-licensed YB-101 (anti-TSHR antibody) from GenSci in Dec 2025 for Graves' disease and thyroid eye disease outside China.
FDA cleared IND for GD in March 2026; Fast Track designation granted May 20, 2026.
Initiated combined Phase 2a/2b trial in June 2026; Phase 2a data expected H2 2027.
Merger with Yarrow Bioscience Operating Company Corp. (formerly Yarrow Bioscience, Inc.) reflected in business update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.